Fátima Marín retweeted
bioRxiv has a dedicated section for negative results.
Use it.
Share negative results.
Your colleagues will appreciate it.
Fátima Marín retweeted
New #JITC article: Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies bit.ly/3EiJBUN
@jcastilloiturra @mariapellise1 @MoreiraR_Leti @merydacaalvarez @MartaPinedaRiu @frankbalaguer @hospitalclinic @idibell_cat
Fátima Marín retweeted
La síndrome de Lynch augmenta el risc de tenir càncer d'endometri. La recerca que lidera Gabriel Capellà, de l'@ICO_oncologia - @idibell_cat, vol personalitzar la prevenció d'aquest càncer mitjançant l'empoderament de la dona en la presa de decisions dels tractaments
🚨𝗪𝗲 𝗮𝗿𝗲 𝗵𝗶𝗿𝗶𝗻𝗴!
We are looking for a #bioinformatician to join our group at @idibell_cat! Work with NGS & omic analyses. More about us: bit.ly/3DtvJ9M
➡️ Collaborative research
➡️ Projects in hereditary cancer
‼️Info & applications👇
bit.ly/4iI9gVe
Fátima Marín retweeted
We are hiring! Looking for a postdoctoral researcher to work on pancreatic cancer modelling. A joint collaboration between hereditarycancergroup.com and p-cmrc.cat/research/rovira-g… @idibell_cat
Job application link: idibell.fundanetsuite.com/co…
A comprehensive analysis of series of patients with CMMRD-associated lymphomas collected through international collaboration.
onlinelibrary.wiley.com/doi/…
Fátima Marín retweeted
Researchers develop and optimize the hs-MSI genetic test🧬, which will improve #CMMRD diagnosis, a rare cancer predisposition in children. This tool will also help refine their clinical prognosis, making them candidates to #immunotherapy
Read more 👉 idibell.cat/en/2024/07/a-gen…
Fátima Marín retweeted
How do mismatch repair-deficient (MMRd) cancers trade off the evolutionary costs and benefits of elevated mutation rates?
Delighted to share our paper on adaptive mutability in MMRd colorectal cancer (CRC) @NatureGenet
nature.com/articles/s41588-0…
Tweetorial 🧵below
Fátima Marín retweeted
I am SUPER thrilled to announce that we have launched the Network for Rare Tumors of the Ovary website!!! A community meeting point for Patients, Researchers, Advocates and Clinicians interested in Rare Ovarian Tumors like SCCOHT and SCSTs. The NRTO explained in a thread:
Fátima Marín retweeted
#InSiGHT2024 in Barcelona has just finished. We have had really good science and fun!
Very proud of @FatimaMarinn and @elisabetmunte presentations on CMMRD in Spain and open-source PMS2 pipeline.
See you all in Singapore!
@idibell_cat @ICO_oncologia
Fátima Marín retweeted
Harvard is offering free research courses.
No fees are required.
Here are 9 courses you don't want to miss:
Fátima Marín retweeted
🔥 Highly sensitive microsatellite instability assay is a robust ancillary test for Constitutional Mismatch Repair Deficiency diagnosis, able to distinguish PMS2 biallelic carriers. @idibell_cat @ICO_oncologia @MartaPinedaRiu @FatimaMarinn
#MedTwitter
👇 buff.ly/4adStVk
Fátima Marín retweeted
Very happy to share with you our last publication on CMMRD! Thank you very much to Fátima Marín, Julia Canet-Hermida and our great collaborators!
#hereditarycancer #CMMRD @Uri_Tabori @ICO_oncologia @idibell_cat
🔥 Highly sensitive microsatellite instability assay is a robust ancillary test for Constitutional Mismatch Repair Deficiency diagnosis, able to distinguish PMS2 biallelic carriers. @idibell_cat @ICO_oncologia @MartaPinedaRiu @FatimaMarinn
#MedTwitter
👇 buff.ly/4adStVk



















